Industry veteran Miguel Forte navigates new kid on the block Kiji Therapeutics into the clinic to prove cell therapy manufacturing doesn’t need to decelerate commercial viability.

Influencer marketing has emerged as a potent tool for many industries and is a sector set to be worth $22bn in its own right by 2025.

Arun Krishna reveals portfolio plans for best-selling therapy Tagrisso, and its other activities to prevent, screen and diagnose lung cancer faster.

In Vivo talks to investors, analysts and companies in rare disease about the challenges they face to innovate and to grow.

Launching a novel drug into a new market is tough. UCB’s Kimberly Moran, talked to In Vivo about how being both patient and digital first gives the company a competitive commercial advantage in an increasingly growing market.

Decades after it was first mentioned, the updated European patent system – which includes the Unitary Patent and the Unified Patent Court – has finally materialized. What impact will this have on originator and generic pharma?